Canopy Growth(US:CGC) Yahoo Finance·2025-09-16 14:27Core Insights - Canopy Growth Corporation (NASDAQ:CGC) reported Q1 FY2026 net revenue of $72.1 million, representing a 9% year-over-year increase driven by a 13% rise in medical cannabis sales and a 43% increase in adult-use cannabis sales in Canada [1] - The company experienced a decline in consolidated gross margin from 35% to 25% due to lower high-margin sales in Poland and a shift towards higher-cost manufactured products [1] - The net loss from continuing operations decreased by 21% to $23 million, while SG&A expenses also fell by 21% as part of $17 million in annualized cost savings [1] Financial Performance - Q1 FY2026 net revenue: $72.1 million, up 9% year-over-year [1] - Medical cannabis sales increased by 13% [1] - Adult-use cannabis sales in Canada rose by 43% to $27 million [1] - International cannabis revenue increased by 5% to $8.8 million [1] - Storz & Bickel vaporizer revenue decreased by 25% to $15.1 million [1] - Consolidated gross margin declined from 35% to 25% [1] - Net loss from continuing operations fell by 21% to $23 million [1] - SG&A expenses decreased by 21% [1] - Cash and short-term investments rose to $144 million [1] Strategic Outlook - CEO Luc Mongeau highlighted significant share growth in cannabis markets with high demand [2] - Interim CFO Tom Stewart noted improving gross margins as a key target for FY2026 [2] - A new Storz & Bickel vaporizer is set to be introduced later in 2025 [2] - The company anticipates that automation and increased PRJ production will enhance margins in the second half of FY2026 [2]